BioAtla
BioAtla
BCAB
NASDAQ
0.34
USD
0.00%
About
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor.
The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications.
BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 694.7K |
| Three Month Average Volume | 18.9M |
| High Low | |
| Fifty-Two Week High | 4.02 USD |
| Fifty-Two Week Low | 1.14 USD |
| Fifty-Two Week High Date | 04 Apr 2024 |
| Fifty-Two Week Low Date | 09 Jul 2024 |
| Price and Volume | |
| Current Price | 1.77 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 5.37% |
| Thirteen Week Relative Price Change | 9.52% |
| Twenty-Six Week Relative Price Change | -43.52% |
| Fifty-Two Week Relative Price Change | -43.72% |
| Year-to-Date Relative Price Change | -39.24% |
| Price Change | |
| One Day Price Change | -2.75% |
| Thirteen Week Price Change | 17.22% |
| Twenty-Six Week Price Change | -37.89% |
| Five Day Price Change | -6.35% |
| Fifty-Two Week Price Change | -29.48% |
| Year-to-Date Price Change | -28.05% |
| Month-to-Date Price Change | -2.21% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.46996 USD |
| Book Value Per Share (Most Recent Quarter) | 0.64913 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.46996 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.64913 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.26682 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.5841 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.17795 USD |
| Normalized (Last Fiscal Year) | -2.5841 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.5841 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.17795 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.5841 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.17795 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.31856 USD |
| Cash Per Share (Most Recent Quarter) | 1.27596 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.55854 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.15379 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.2344 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -5,205 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -6,651.71% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -6,715.89% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -6,651.71% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -37.01% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 41.68% |
| EPS Change (Trailing Twelve Months) | 17.74% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -61,662,000 |
| Net Debt (Last Fiscal Year) | -111,471,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -104,113,000 |
| Free Cash Flow (Trailing Twelve Months) | -107,321,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -71.49% |
| Return on Assets (Trailing Twelve Months) | -84.23% |
| Return on Assets (5 Year) | -48.72% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -98.37% |
| Return on Equity (Trailing Twelve Months) | -134.14% |
| Return on Equity (5 Year) | -90.21% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -84.01% |
| Return on Investment (Trailing Twelve Months) | -106.06% |
| Return on Investment (5 Year) | -57.35% |